Original ArticlesrhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial
Keywords
Abbreviations
Cited by (0)
Detailed affiliations available at www.jpeds.com
Funded by Shire. Shire participated in the design of the study, the collection and analysis of data, and preparation of the clinical study report. D.L. and I.H-P. hold stock/stock options in Premalux AB, and received consulting fees from Shire. B.H. received consulting fees from Premacure AB and Shire. L.R. received consulting fees and research support from Shire. N.M. received consulting fees from Shire, and partial funding from the Department of Health's National Institute for Health Research Biomedical Research Centre's funding scheme at University College London Hospitals/University College London. K.B., F.B., J.H., O.M-N., M.vW., and L.S. received consulting fees from Shire. D.D. received consulting fees from Shire, and received consulting fees from Ipsen regarding other indications for IGF-1 therapies. N.B., A.T., M.H., E.J., A.M., and J-K.C. are employees of and own stock/stock options in Shire. M.T.'s university received consulting fees from Shire. A.H. holds stock/stock options in Premalux AB, and received consulting fees from Shire. C.D., A.M., P.R, and C.G. declare no conflicts of interest.
- *
List of additional members of the study team is available at www.jpeds.com (Appendix 1).